Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SPNE

DatePrice TargetRatingAnalyst
11/2/2022$12.00 → $6.75Buy → Hold
Truist
4/22/2022$27.00 → $21.00Overweight
Cantor Fitzgerald
4/13/2022$20.00Buy
Truist
12/21/2021$25.00 → $20.00Buy
Truist Securities
10/28/2021$100.00Buy
Loop Capital
More analyst ratings

$SPNE
Press Releases

Fastest customizable press release news feed in the world

See more
  • SeaSpine Announces 100th Placement of 7D FLASH™ Navigation System

    CARLSBAD, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the placement of its 100th 7D FLASH™ Navigation System globally. The 7D FLASH™ Navigation System uses visible light to create a three-dimensional image for surgical navigation in just seconds, which is expected to result in shorter and more efficient spinal procedures with less radiation exposure. It is the only marketed image-guidance system that utilizes novel and proprietary camera-based technology, coupled with machine-vision algorithms, to eliminate the long-standing fru

    $SPNE
    Medical Specialities
    Health Care
  • Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

    Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic will serve as Chief Financial Officer (CFO) for the new combined company, effective upon the completion of their pending merger. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221118005106/en/ Bostjancic currently serves as the CFO and Chief Operating Officer of SeaSpine, roles he has held since 2015 and 2022 respectively. Previously, Bostjancic served as Treasurer and Sen

    $OFIX
    $SPNE
    Medical/Dental Instruments
    Health Care
    Medical Specialities
  • Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

    LEWISVILLE, Texas and CARLSBAD, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic will serve as Chief Financial Officer (CFO) for the new combined company, effective upon the completion of their pending merger. Bostjancic currently serves as the CFO and Chief Operating Officer of SeaSpine, roles he has held since 2015 and 2022 respectively. Previously, Bostjancic served as Treasurer and Senior Vice President from 2015 through 2022, and as

    $OFIX
    $SPNE
    Medical/Dental Instruments
    Health Care
    Medical Specialities

$SPNE
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SPNE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SPNE
SEC Filings

See more

$SPNE
Leadership Updates

Live Leadership Updates

See more
  • SeaSpine® Announces New Senior Leadership Team Appointments

    CARLSBAD, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic, previously the Company's Senior Vice President, Chief Financial Officer, has assumed expanded responsibilities and the title of Chief Operating and Financial Officer. In addition, the Company announced that Hollis Winkler joined the Company as Senior Vice President, Human Resources. With her hiring, Ms. Winkler joined the SeaSpine Senior Leadership Team. Mr. Bostjancic has served as SeaSpine's Chief Financial Officer since 2015. He has been an influentia

    $SPNE
    Medical Specialities
    Health Care
  • SeaSpine® Announces New Senior Leadership Team Appointments

    CARLSBAD, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the elevation of Dr. Frank Vizesi to Chief Scientific Officer and Shaeffer Bannigan to Vice President, Product Development, Spinal Implants. With his promotion, Mr. Bannigan joins the SeaSpine Senior Leadership Team. Dr. Vizesi joined SeaSpine in 2015 as Director, Research and Development, Orthobiologics. He quickly elevated the approach and defined the vision for delivering best-in-class orthobiologics procedural solutions. Under Dr. Vizesi's leadership, the team deepened

    $SPNE
    Medical Specialities
    Health Care
  • SeaSpine Appoints Seasoned Healthcare Executive to its Board of Directors

    CARLSBAD, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it has appointed Angela Steinway to its Board of Directors, effective December 14, 2021. Ms. Steinway will serve as a member of the company's Audit Committee. With the appointment of Ms. Steinway, the SeaSpine Board of Directors now consists of nine directors, eight of whom are independent. Ms. Steinway brings over 15 years of experience in the medical device industry, having worked in various strategy, sales and finance functions throughout her career. Currently, she i

    $SPNE
    Medical Specialities
    Health Care

$SPNE
Financials

Live finance-specific insights

See more
  • SeaSpine to Report Third Quarter 2022 Financial Results on November 1, 2022

    CARLSBAD, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release third quarter financial results after the close of trading on Tuesday, November 1, 2022. Members of the Company's management team will host a corresponding conference call and webcast beginning at 1:30 pm PT / 4:30 pm ET. To listen to the live webcast and a replay, please visit the Investors section of the SeaSpine website at: https://www.seaspine.com/. About SeaSpine SeaSpine (www.seaspine.com) is a global medical technology company focused on the des

    $SPNE
    Medical Specialities
    Health Care
  • Orthofix and SeaSpine to Combine in Merger of Equals to Create Leading Global Spine and Orthopedics Company

    Highly complementary spine and orthopedics portfoliosOne of the industry's broadest biologics and regenerative technology offeringsDifferentiated and synergistic enabling technologiesMeaningful cross-selling revenue synergies and cost savingsFinancial strength to pursue growth investments without need for immediate equity financing Expected to be adjusted EBITDA accretive to Orthofix by the second year following close including cost savings Companies to host joint conference call and webcast today at 8:00 a.m. ET LEWISVILLE, Texas and CARLSBAD, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) --  Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpin

    $OFIX
    $SPNE
    Medical/Dental Instruments
    Health Care
    Medical Specialities
  • SeaSpine Reports 19% Revenue Growth and Record Quarterly Revenue for Second Quarter 2022 and Raises Full Year 2022 Revenue Guidance

    CARLSBAD, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today second quarter financial results for the three-months ended June 30, 2022. Summary Second Quarter 2022 Financial Results and Recent Highlights Total revenue of $56.3 million, an increase of 19% year-over-yearU.S. revenue of $49.5 million, an increase of 16% year-over-year U.S. spinal implants and enabling technologies revenue of $25.0 million, an increase of 17% year-over-yearU.S. orthobiologics revenue of $24.5 million, an increase of 16% year-over-year International reve

    $SPNE
    Medical Specialities
    Health Care

$SPNE
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more